Sionna Therapeutics Stock News

Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity

LOS ANGELES--(BUSINESS WIRE)---- $SION--SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law.

SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating potential violations of the federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). Click here to join the investigation.

The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.

Sionna Therapeutics said on Monday it would stop developing its experimental drug as an addition to ​standard treatment for a type of genetic ‌disorder after it failed to show a meaningful benefit in a mid-stage trial.

PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026